Issue Date: August 28, 2017
AstraZeneca, Ethris sign mRNA agreement
AstraZeneca will pay Ethris roughly $30 million as part of a five-year collaboration to develop RNA therapies for respiratory diseases. Under the pact, Ethris will develop messenger RNA therapies based on its technology, which allows a nonimmunogenic transcript to be delivered into cells. The companies will work on treatments for asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. Since 2013 AstraZeneca has been working with Moderna Therapeutics to develop mRNA-based drugs for cardiovascular, metabolic, and renal diseases.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society